NO753578L - - Google Patents

Info

Publication number: NO753578L
Authority: NO; Norway
Prior art keywords: stated; coli; enterotoxin; buffer; carried out
Prior art date: 1974-11-01

Application number

NO753578A

Other languages

English (en)

Norwegian (no)

Inventor

F Dorner

G Laber

P Mayer

E Schuetze

R Weil

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-11-01

Filing date

1975-10-24

Publication date

1976-05-04

1974-11-01 Priority claimed from CH1467174A external-priority patent/CH612994A5/de

1975-05-12 Priority claimed from CH604075A external-priority patent/CH615196A5/de

1975-10-24 Application filed by Sandoz Ag filed Critical Sandoz Ag

1976-05-04 Publication of NO753578L publication Critical patent/NO753578L/no

Links

239000000147 enterotoxin Substances 0.000 claims description 86
231100000655 enterotoxin Toxicity 0.000 claims description 86
101710146739 Enterotoxin Proteins 0.000 claims description 69
241000588724 Escherichia coli Species 0.000 claims description 69
238000000034 method Methods 0.000 claims description 67
239000000872 buffer Substances 0.000 claims description 47
238000000926 separation method Methods 0.000 claims description 28
102000030621 adenylate cyclase Human genes 0.000 claims description 25
108060000200 adenylate cyclase Proteins 0.000 claims description 25
239000000706 filtrate Substances 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 19
239000000523 sample Substances 0.000 claims description 18
229920000936 Agarose Polymers 0.000 claims description 16
239000003792 electrolyte Substances 0.000 claims description 16
238000002523 gelfiltration Methods 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 16
238000002218 isotachophoresis Methods 0.000 claims description 13
239000002609 medium Substances 0.000 claims description 13
150000002270 gangliosides Chemical class 0.000 claims description 12
238000011534 incubation Methods 0.000 claims description 12
239000000047 product Substances 0.000 claims description 12
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 11
230000007895 enterotoxin activity Effects 0.000 claims description 11
239000000959 ampholyte mixture Substances 0.000 claims description 10
230000000369 enteropathogenic effect Effects 0.000 claims description 10
108010050327 trypticase-soy broth Proteins 0.000 claims description 10
239000003446 ligand Substances 0.000 claims description 9
239000001974 tryptic soy broth Substances 0.000 claims description 9
229920005654 Sephadex Polymers 0.000 claims description 8
239000012507 Sephadex™ Substances 0.000 claims description 8
238000010828 elution Methods 0.000 claims description 8
229920002401 polyacrylamide Polymers 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
239000000758 substrate Substances 0.000 claims description 7
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical group Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
PVKSNHVPLWYQGJ-KQYNXXCUSA-N AMP-PNP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)NP(O)(O)=O)[C@@H](O)[C@H]1O PVKSNHVPLWYQGJ-KQYNXXCUSA-N 0.000 claims description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 6
230000002107 myocardial effect Effects 0.000 claims description 6
239000013612 plasmid Substances 0.000 claims description 6
238000000746 purification Methods 0.000 claims description 6
239000011347 resin Substances 0.000 claims description 6
229920005989 resin Polymers 0.000 claims description 6
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 5
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
241000282326 Felis catus Species 0.000 claims description 5
229940113721 aminocaproate Drugs 0.000 claims description 5
229940098773 bovine serum albumin Drugs 0.000 claims description 5
238000013375 chromatographic separation Methods 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 5
238000000855 fermentation Methods 0.000 claims description 5
230000004151 fermentation Effects 0.000 claims description 5
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
229920002684 Sepharose Polymers 0.000 claims description 4
235000012538 ammonium bicarbonate Nutrition 0.000 claims description 4
239000013068 control sample Substances 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
150000004665 fatty acids Chemical class 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
239000012429 reaction media Substances 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
150000003904 phospholipids Chemical class 0.000 claims description 3
125000006850 spacer group Chemical group 0.000 claims description 3
229960000278 theophylline Drugs 0.000 claims description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical group [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 2
101710095468 Cyclase Proteins 0.000 claims description 2
229930186217 Glycolipid Natural products 0.000 claims description 2
235000021314 Palmitic acid Nutrition 0.000 claims description 2
239000001099 ammonium carbonate Substances 0.000 claims description 2
229950010030 dl-alanine Drugs 0.000 claims description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 claims description 2
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
125000005122 aminoalkylamino group Chemical group 0.000 claims 1
MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims 1
125000002421 ganglioside group Chemical group 0.000 claims 1
229960002337 magnesium chloride Drugs 0.000 claims 1
239000000499 gel Substances 0.000 description 33
238000012360 testing method Methods 0.000 description 31
239000000243 solution Substances 0.000 description 25
239000003053 toxin Substances 0.000 description 21
231100000765 toxin Toxicity 0.000 description 21
108700012359 toxins Proteins 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
208000015181 infectious disease Diseases 0.000 description 14
239000000203 mixture Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
230000001717 pathogenic effect Effects 0.000 description 13
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
229960005486 vaccine Drugs 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
239000000427 antigen Substances 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
239000002244 precipitate Substances 0.000 description 10
IVOMOUWHDPKRLL-KQYNXXCUSA-M 3',5'-cyclic AMP(1-) Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-M 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
230000001147 anti-toxic effect Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
206010008631 Cholera Diseases 0.000 description 8
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
230000003053 immunization Effects 0.000 description 8
238000002649 immunization Methods 0.000 description 8
238000000760 immunoelectrophoresis Methods 0.000 description 7
235000019333 sodium laurylsulphate Nutrition 0.000 description 7
-1 "AG 501-X8" Chemical compound 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000004202 carbamide Substances 0.000 description 6
210000001035 gastrointestinal tract Anatomy 0.000 description 6
239000007788 liquid Substances 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
239000001888 Peptone Substances 0.000 description 5
108010080698 Peptones Proteins 0.000 description 5
238000001042 affinity chromatography Methods 0.000 description 5
239000007853 buffer solution Substances 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
235000019319 peptone Nutrition 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
206010012735 Diarrhoea Diseases 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
239000008351 acetate buffer Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000003022 colostrum Anatomy 0.000 description 4
235000021277 colostrum Nutrition 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
229960000789 guanidine hydrochloride Drugs 0.000 description 4
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
241001646716 Escherichia coli K-12 Species 0.000 description 3
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
241000282324 Felis Species 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
241000607626 Vibrio cholerae Species 0.000 description 3
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001718 carbodiimides Chemical class 0.000 description 3
239000003480 eluent Substances 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
238000001155 isoelectric focusing Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000011002 quantification Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FOWCHXWYEPAHAL-UHFFFAOYSA-N 6,6,6-triaminohexanoic acid Chemical compound NC(CCCCC(=O)O)(N)N FOWCHXWYEPAHAL-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
239000006161 blood agar Substances 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000000688 enterotoxigenic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000005189 flocculation Methods 0.000 description 2
230000016615 flocculation Effects 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036512 infertility Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000004153 renaturation Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
239000000344 soap Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
239000011800 void material Substances 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
241001302580 Escherichia coli ETEC H10407 Species 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
101000693916 Gallus gallus Albumin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
231100000757 Microbial toxin Toxicity 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
241000220317 Rosa Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000037175 Travel-Related Illness Diseases 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
108010027252 Trypsinogen Proteins 0.000 description 1
102000018690 Trypsinogen Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000005263 alkylenediamine group Chemical group 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
230000006378 damage Effects 0.000 description 1
OWEZJUPKTBEISC-UHFFFAOYSA-N decane-1,1-diamine Chemical compound CCCCCCCCCC(N)N OWEZJUPKTBEISC-UHFFFAOYSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000009413 insulation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
RVPVRDXYQKGNMQ-UHFFFAOYSA-N lead(2+) Chemical compound [Pb+2] RVPVRDXYQKGNMQ-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000011941 photocatalyst Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
125000005629 sialic acid group Chemical group 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000007888 toxin activity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO753578A 1974-11-01 1975-10-24 NO753578L (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CH1467174A CH612994A5 (en)	1974-11-01	1974-11-01	Process for the preparation of coli enterotoxin
CH1645874		1974-12-11
CH1645974		1974-12-11
CH604075A CH615196A5 (en)	1975-05-12	1975-05-12	Purification process for coli enterotoxin

Publications (1)

Publication Number	Publication Date
NO753578L true NO753578L (da)	1976-05-04

Family

ID=27428963

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO753578A NO753578L (da)	1974-11-01	1975-10-24

Country Status (16)

Country	Link
JP (1)	JPS5170810A (da)
AU (1)	AU511934B2 (da)
CA (1)	CA1053152A (da)
DD (1)	DD124879A5 (da)
DE (1)	DE2547224A1 (da)
DK (2)	DK478575A (da)
ES (1)	ES442242A1 (da)
FI (2)	FI752964A7 (da)
FR (1)	FR2289206A1 (da)
GB (1)	GB1529871A (da)
IE (1)	IE43702B1 (da)
IL (1)	IL48384A (da)
NL (1)	NL7512590A (da)
NO (1)	NO753578L (da)
NZ (1)	NZ179108A (da)
SE (1)	SE8100404L (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4740585A (en) *	1984-07-30	1988-04-26	The Board Of Trustees Of The Leland Stanford Junior University	Synthetic vaccine against urinary infections
IL78775A (en) *	1985-05-15	1992-06-21	Biotech Australia Pty Ltd	Oral vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA738364B (en) *	1972-12-04	1974-09-25	Rit Rech Ind Therapeut	Piglet colibacillosis vaccines and process for their preparation

1975
- 1975-10-22 DE DE19752547224 patent/DE2547224A1/de not_active Ceased
- 1975-10-23 FI FI752964A patent/FI752964A7/fi not_active Application Discontinuation
- 1975-10-23 DK DK478575A patent/DK478575A/da unknown
- 1975-10-24 NO NO753578A patent/NO753578L/no unknown
- 1975-10-28 NL NL7512590A patent/NL7512590A/xx not_active Application Discontinuation
- 1975-10-28 GB GB44308/75A patent/GB1529871A/en not_active Expired
- 1975-10-29 IE IE2352/75A patent/IE43702B1/en unknown
- 1975-10-30 DD DD189144A patent/DD124879A5/xx unknown
- 1975-10-30 CA CA238,673A patent/CA1053152A/en not_active Expired
- 1975-10-30 IL IL48384A patent/IL48384A/xx unknown
- 1975-10-30 NZ NZ179108A patent/NZ179108A/xx unknown
- 1975-10-30 ES ES442242A patent/ES442242A1/es not_active Expired
- 1975-10-31 JP JP50132085A patent/JPS5170810A/ja active Pending
- 1975-10-31 FR FR7533471A patent/FR2289206A1/fr active Granted
- 1975-11-03 AU AU86282/75A patent/AU511934B2/en not_active Expired
1978
- 1978-06-20 DK DK278478A patent/DK278478A/da unknown
- 1978-09-14 FI FI782827A patent/FI782827A7/fi not_active Application Discontinuation
1981
- 1981-01-23 SE SE8100404A patent/SE8100404L/sv unknown

Also Published As

Publication number	Publication date
AU8628275A (en)	1977-05-12
FR2289206B1 (da)	1978-11-10
AU511934B2 (en)	1980-09-11
FI752964A7 (da)	1976-05-02
NL7512590A (en)	1976-05-04
DD124879A5 (da)	1977-03-16
NZ179108A (en)	1978-07-28
JPS5170810A (da)	1976-06-18
SE8100404L (sv)	1981-01-23
DK478575A (da)	1976-05-02
GB1529871A (en)	1978-10-25
CA1053152A (en)	1979-04-24
IE43702L (en)	1976-05-01
IL48384A0 (en)	1976-03-31
FI782827A7 (fi)	1978-09-14
IE43702B1 (en)	1981-05-06
FR2289206A1 (fr)	1976-05-28
IL48384A (en)	1979-05-31
DK278478A (da)	1978-06-20
ES442242A1 (es)	1977-08-01
DE2547224A1 (de)	1976-05-13

Publication	Publication Date	Title
Une et al.	1984	Roles of V antigen in promoting virulence and immunity in yersiniae.
Skurnik et al.	1984	Virulence plasmid-associated autoagglutination in Yersinia spp
KR100242179B1 (ko)	2000-08-01	디스크 드라이브 데이타경로 보전 제어구조
KR100240974B1 (ko)	2000-08-01	트란스페린 수용체 단백질을 함유하는 백신
Verstreate et al.	1982	Outer membrane proteins of Brucella abortus: isolation and characterization
Getchell et al.	1985	Comparison of Renibacterium salmoninarum isolates by antigenic analysis
Evans et al.	1979	Purification and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli
US5597572A (en)	1997-01-28	Method of producing Neisseria meningitidis B vaccine, and vaccine produced by method
Banerjee-Bhatnagar et al.	1990	Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines
Klipstein et al.	1985	Immunological relationship of the B subunits of Campylobacter jejuni and Escherichia coli heat-labile enterotoxins
Chopra et al.	1987	Cloning and expression of the Salmonella enterotoxin gene
Nachmias et al.	1982	Comparison of protein-lipopolysaccharide complexes produced by pathogenic and non-pathogenic strains of Verticillium dahliae Kleb. from potato
PL126748B1 (en)	1983-08-31	Method of obtaining thermally stable derivative of e. coli enterotoxin
Peterson et al.	1979	Evidence of a role for permeability factors in the pathogenesis of salmonellosis
CA1340372C (en)	1999-02-02	Production of e. coli lt-b enterotoxin subunit
Lachmann et al.	1986	Solubilization and characterization of surface antigenic components of Erysipelothrix rhusiopathiae T28
Lallier et al.	1980	Escherichia coli heat-stable enterotoxin: rapid method of purification and some characteristics of the toxin
DE68928529T2 (de)	1998-04-16	Expression der bindenden Untereinheit des Choleratoxins mit Hilfe von fremden Promotoren und/oder Leadersequenzen
Walia et al.	1999	Purification and characterization of novel toxin produced by Vibrio cholerae O1
Stewart et al.	1986	Cross‐protection from Bacteroides nodosus vaccines and the interaction of pili and adjuvants
Frandsen et al.	1991	Characterization of toxin from different strains of Pasteurella multocida serotype A and D
Kapitany et al.	1979	Isolation and partial characterization of two different heat-stable enterotoxins produced by bovine and porcine strains of enterotoxigenic Escherichia coli
CN116063414B (zh)	2025-11-07	一种人工c型副鸡禽杆菌免疫保护性抗原蛋白及其应用
IE43702B1 (en)	1981-05-06	E.coli enterotoxin purification
CN100406472C (zh)	2008-07-30	一种眼镜蛇神经毒素蛋白的融合可溶表达、重组毒素的酸解释放及其生产纯化方法